PULTE FAMILY CHARITABLE FOUNDATION LAUNCHES NONPROFIT, THE CATHOLIC INITIATIVE
Groundbreaking, Vatican-Approved Funding Model Created to Restore and Endow Vibrant Catholic Churches, Schools, and Parishes in Perpetuity
BOCA RATON, Fla., March 9, 2025 /PRNewswire/ -- The Pulte Family Charitable Foundation, a nonprofit organization supporting humanitarian works worldwide, today announced the launch of The Catholic Initiative, an innovative, Vatican-approved funding model created to restore and endow vibrant Catholic churches, schools, and parishes for generations to come.
The model is the first of its kind in the world in faith-based fundraising and shifts ownership of church buildings and campuses to a newly created nonprofit organization created solely for this purpose, with The Catholic Initiative assuming responsibility for restoring and maintaining the property going forward. Through iron clad, 200-year leases, The Catholic Initiative ensures that parishes retain exclusive and permanent rights to use the sites as Catholic churches and schools, without the risk of funds being redirected to other priorities. Catholic Initiative fundraising then goes to establishing an endowment to provide for future capital and operational needs, support repairs, routine maintenance, and the financial support of an onsite priest.
The Pulte Family Charitable Foundation, founded by William J. Pulte, a devout Catholic, master builder and philanthropist, is guided by the belief in the inherent dignity of all persons and works to meet the basic human needs of the most marginalized members of the human family, including socioeconomically disadvantaged youth; the aged; persons with physical, emotional, and mental disabilities; and those with the fewest material resources. During William J. Pulte's lifetime, he donated hundreds of millions of dollars to Catholic churches and causes. The Foundation's current generation of leadership wished to continue that legacy while creating a philanthropic model that ensures sustainable funding for generations to come.
'The Foundation was built on the ethos of 'to whom much is given, much will be required,' and a commitment to embodying an entrepreneurial spirit—finding new ways to solve challenges,' said Kevin Doyle, Chief Operating Officer for the Pulte Family Foundation and President of the Catholic Initiative. 'The Catholic Initiative honors that ethos by pioneering a new model of investing in vibrant churches, schools, and parishes in underserved communities, ensuring their long-term sustainability. This model frees religious leaders and Catholic educators from their financial burdens and allows them to focus on their true mission: serving their parishioners and students.'
During the past 30 years, more than 2,000 Catholic schools have closed, along with roughly 2,600 Catholic parishes, representing not just the loss of physical spaces but community hubs central to parishioner life. The Catholic Initiative provides sustained support over generations, allowing priests to focus on their missionary efforts and not on perpetual fundraising.
The Catholic Initiative is launching with three flagship projects aimed at investing in vibrant Catholic communities where the lack of financial resources is holding back their potential. First, it is undertaking a full restoration of the historic Basilica of Ste. Anne in Detroit, Michigan, along with sustaining an endowment to secure its future. Second, it is securing the property ownership of Chicago's oldest Catholic all-girls high school – Josephinum Academy of the Sacred Heart – and establishing an endowment to support the long-term vitality of the school. Third, it is raising an endowment for Bulldog Catholic, the thriving campus ministry led by Fr. Mike Schmitz, which is dedicated to forming and inspiring the next generation of young Catholics. Two additional projects in the Midwest are currently in development and will be announced in the coming months.
The Pulte Family Foundation's transformative leadership has drawn the attention of major partners nationwide. Among them is Fr. Mike Schmitz, a widely respected Catholic priest and host of the popular podcasts Bible in a Year and The Catechism in a Year produced by Ascension. In addition to his chaplaincy at the University of Minnesota Duluth, he has joined the Board of Advisors for The Catholic Initiative and will play an active role in guiding and supporting each of its projects.
'I was deeply inspired by the vision and innovation behind The Catholic Initiative,' said Fr. Schmitz. 'This model isn't just about financial support, it's about unleashing the full potential of Catholic churches, schools, and parishes. Many Catholic communities are vibrant and alive with faith, they just need the resources to thrive for generations. I felt called to be part of something that can truly transform the future of the Catholic faith.'
The Catholic Initiative is part of a series of 'Legacy of Hope' Projects that the Pulte Family Charitable Foundation is spearheading. These efforts aim to usher in a new era of philanthropy with creative models of giving designed to sustain and transform communities for generations, uplift the marginalized, and secure the future of faith and service. These scalable models are setting a new standard for making strategic, impact-driven philanthropic investments/gifts.
'Our goal with The Catholic Initiative is to build a model that will transform lives for generations to come,' Kevin Doyle said. 'We hope we can shift the conversation for priests and parishioners—from one of constant fundraising to one of renewal, sustainability, and the needs of the community.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Rand Paul, Mike Lee back Elon Musk over Trump-backed bill: ‘We can and must do better'
Republican Sens. Rand Paul (Ky.) and Mike Lee (Utah) are backing tech billionaire Elon Musk's criticism of the House-approved version of President Trump's agenda-setting megabill as it heads to the upper chamber for vetting. 'We can and must do better,' Paul wrote on the social platform X on Tuesday in response to Musk's post that slammed the One Big Beautiful Bill Act as a 'disgusting abomination.' Lee also chimed in, writing, 'The Senate must make this bill better,' in a reply to Musk. Musk's blistering critique of the measure touted by Trump and House Republican leaders comes just days after the end of Musk's White House role as a special adviser on government spending and de facto head of the Trump administration's Department of Government Efficiency (DOGE). 'I'm sorry, but I just can't stand it anymore. This massive, outrageous, pork-filled Congressional spending bill is a disgusting abomination,' Musk wrote on X, the platform that he owns. 'Shame on those who voted for it: you know you did wrong. You know it.' The massive tax and spending legislation would extend Trump's 2017 tax cuts and boost funding for border and defense priorities, while slashing spending on social safety net programs like Medicaid and food assistance. It narrowly passed the GOP-controlled House in May and is now up for Senate review. But Paul and other senators already have highlighted projections that it would add nearly $4 trillion to the national debt. Musk voiced tepid disapproval of the measure in a 'CBS Sunday Morning' interview over the weekend and said it 'it undermines the work that the DOGE team is doing.' 'I think a bill can be big, or it could be beautiful,' Musk said in the interview. 'I don't know if it could be both — my personal opinion.' But the more forceful rebuke marked a turn in his criticism and defense of his efforts to curb government waste. 'It will massively increase the already gigantic budget deficit to $2.5 trillion (!!!) and burden America citizens with crushingly unsustainable debt,' he wrote in a follow-up post on Tuesday. But the White House dismissed the criticism from Musk, who was a top donor to Trump's reelection campaign last fall. 'The president already knows where Elon Musk stood on this bill,' White House press secretary Karoline Leavitt told reporters during Tuesday's press briefing. 'It doesn't change his opinion.' Trump lashed out at Paul on Truth Social earlier Tuesday, accusing the Kentucky lawmaker of voting 'NO on everything' and 'never' having 'practical or constructive ideas.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Essential Thrombocythemia Market to Witness Robust Growth During the Forecast Period (2025-2034) Amid Rising R&D Activity
Beyond PEGASYS, the essential thrombocythemia treatment landscape is evolving with several promising assets in the pipeline. These include BESREMi (ropeginterferon alfa-2b), Bomedemstat (MK-3543/IMG-7289), Pelabresib (CPI-0610), Dencatistat (STP 938), INCA033989, and VAC85135. LAS VEGAS, June 3, 2025 /PRNewswire/ -- Essential thrombocythemia is a chronic form of myeloproliferative neoplasm (MPN) marked by an abnormally high platelet count in the bloodstream. It is most frequently diagnosed in women over 50 and involves the excessive production of platelet precursors in the bone marrow. Common complications include blood clots and bleeding, while less frequent but more serious outcomes in advanced stages can involve progression to myelofibrosis or acute leukemia. As of 2024, approximately 167K individuals in the US were diagnosed with essential thrombocythemia, with about 75% of these cases linked to mutations in the JAK2 gene. During the same year, an estimated 85K patients in the US received first-line treatment for essential thrombocythemia. The primary goal of essential thrombocythemia management is to reduce the risk of vascular complications, such as thrombotic and hemorrhagic events, which are major contributors to illness and death. Treatment approaches are guided by a risk stratification system that classifies patients as either low or high risk for thrombosis. Typically, low-risk individuals are younger and have no history of clotting events, while high-risk patients are generally over 60 years old and have experienced thrombosis in the past. Learn more about the essential thrombocythemia cancer @ New Treatment for Essential Thrombocythemia For low-risk patients, aspirin is recommended, provided there are no major contraindications. However, caution is advised when platelet counts exceed 1,000 × 10⁹/L, as this raises the risk of acquired von Willebrand disease. In such cases, if laboratory findings suggest von Willebrand abnormalities, aspirin should be avoided. Aspirin is also the preferred treatment in patients experiencing microvascular complications like erythromelalgia. In contrast, high-risk patients are typically managed with a combination of antiplatelet and cytoreductive therapies. Hydroxyurea is generally considered the first-line agent for cytoreduction. However, anagrelide may be used as an alternative when hydroxyurea is poorly tolerated or ineffective. At present, only one drug is officially approved for the treatment of essential thrombocythemia, and its use is restricted to Europe. There are currently no FDA-approved therapies for essential thrombocythemia in the United States. PEGASYS, a Type I interferon, is made by pegylating interferon alfa-2a, which involves attaching polyethylene glycol (PEG) chains to the molecule. Find out more on FDA-approved essential thrombocythemia drugs @ Essential Thrombocythemia Treatment Options PEGASYS was previously approved by the European Commission (EC) for treating Chronic Hepatitis B in adults and children over 3, and Chronic Hepatitis C in adults and children over 5, in combination with other medications. In August 2024, pharmaand GmbH announced that the EC had granted a Type II variation approval for PEGASYS, allowing its use as a monotherapy for adults with essential thrombocythemia. Various key players are leading the treatment landscape of essential thrombocythemia, such as pharma&, AOP Orphan Pharmaceuticals AG, Merck Sharp and Dohme, Novartis, Incyte Corporation, and others. Discover which therapies are expected to grab major essential thrombocythemia market share @ Essential Thrombocythemia Market Report Bomedemstat (MK-3543) is an experimental small-molecule drug developed by Merck that irreversibly inhibits LSD1, a key regulator of hematopoietic stem cell proliferation, differentiation, and maturation. The drug is under clinical evaluation for various myeloproliferative neoplasms (MPNs), including essential thrombocythemia, myelofibrosis, and polycythemia vera. In 2018, Bomedemstat was granted Orphan Drug Designation (ODD) for essential thrombocythemia treatment. In January 2020, Imago BioSciences received Fast Track Designation (FTD) from the US FDA for bomedemstat for the same indication. By November 2022, Merck announced its acquisition of Imago BioSciences, a clinical-stage biotechnology company focused on bomedemstat for myelofibrosis treatment, for $36 per share in cash, totaling approximately $1.35 billion. This strategic move aimed to strengthen Merck's hematology portfolio and establish its presence in the growing myelofibrosis market. PharmaEssentia is advancing ropeginterferon alfa-2b (P1101) for essential thrombocythemia, offering a biweekly injection regimen aimed at improving tolerability and patient adherence, thereby enhancing therapeutic outcomes. A global Phase III clinical trial for essential thrombocythemia is currently in progress. Participants who respond positively during the initial study period will continue into an extension phase for long-term evaluation. Pelabresib, another investigational therapy, is a selective small molecule targeting BET (bromodomain and extra-terminal domain) proteins, which are involved in gene regulation associated with hematologic malignancies. The ongoing Phase II MANIFEST trial (NCT02158858) is assessing its efficacy in patients with myelofibrosis and high-risk ET through an open-label study. In February 2024, MorphoSys entered into a Business Combination Agreement with Novartis AG, reflecting Novartis's plan to launch a voluntary public takeover offer for all outstanding MorphoSys bearer shares without nominal value. Discover more about drugs for essential thrombocythemia in development @ Essential Thrombocythemia Clinical Trials The anticipated launch of these emerging therapies for essential thrombocythemia are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the essential thrombocythemia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for essential thrombocythemia is expected to grow from USD 417 million in the 7MM in 2024 at a significant CAGR by 2034. The market size of essential thrombocythemia is expected to grow due to several factors, including an increase in the prevalent pool, the expected entry of emerging therapies with novel targets, and attractive pricing in the 7MM. DelveInsight's latest published market report, titled as Essential Thrombocythemia Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the essential thrombocythemia country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The essential thrombocythemia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Diagnosed Prevalent Cases Symptom-specific Cases Gender-specific Cases Mutation-specific Cases Risk-specific Cases Age-specific Cases Total Treated Cases The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM essential thrombocythemia market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this essential thrombocythemia market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the essential thrombocythemia market. Also, stay abreast of the mitigating factors to improve your market position in the essential thrombocythemia therapeutic space. Related Reports Essential Thrombocythemia Epidemiology Essential Thrombocythemia Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the essential thrombocythemia epidemiology trends. Essential Thrombocythemia Pipeline Essential Thrombocythemia Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key essential thrombocythemia companies, including PharmaEssentia, Imago BioSciences, Novartis, Constellation Pharmaceuticals, among others. Polycythemia Vera Market Polycythemia Vera Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key polycythemia vera companies, including IIncyte, Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals, Protagonist Therapeutics, Merck (Imago BioSciences), Italfarmaco, Ionis Pharmaceutical, Silence Therapeutics, Perseus Proteomics, AbbVie, Johnson & Johnson Innovative Medicine, Mabwell (Shanghai) Bioscience, Disc Medicine, GluBio Therapeutics, among others. Polycythemia Vera Pipeline Polycythemia Vera Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key polycythemia vera companies, including Protagonist Therapeutics, Italfarmaco, Ionis Pharmaceuticals, Perseus Proteomics, Agios Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP
Yahoo
an hour ago
- Yahoo
U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer
ORION CORPORATION PRESS RELEASE 3 JUNE 2025 at 23.30 EEST U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer Darolutamide is the first and only in the U.S. and FDA-approved androgen receptor inhibitor (ARi) for the treatment of patients with hormone-sensitive prostate cancer (mHSPC), in combination with androgen deprivation therapy (ADT), with or without chemotherapy. This third approval is based on positive results from the pivotal Phase III ARANOTE trial and broadens the indication profile of darolutamide in mHSPC, enabling its use in combination with ADT, with or without chemotherapy (docetaxel). Darolutamide plus ADT reinforces the established safety and tolerability profile of darolutamide for prostate cancer patients across all approved indications. Orion's collaboration partner Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved the oral androgen receptor inhibitor (ARi) darolutamide in combination with androgen deprivation therapy (ADT) for use in patients with metastatic castration-sensitive prostate cancer (mCSPC), which is also known as metastatic hormone-sensitive prostate cancer (mHSPC). The approval is based on positive results from the pivotal Phase III ARANOTE trial, which showed that darolutamide plus ADT significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001) in patients with mHSPC. With this approval, darolutamide plus ADT is indicated in the U.S. for the treatment of adult patients with mHSPC either with or without docetaxel. In addition, darolutamide is approved for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. Prostate cancer is the second most common cancer in men and the fifth most common cause of cancer death in men worldwide.1 In 2022, an estimated 1.5 million men were diagnosed with prostate cancer, and about 397,000 died from the disease worldwide.1 Prostate cancer diagnoses are projected to increase to 2.9 million by 2040.2 Darolutamide, under the brand name Nubeqa®, is already approved in mHSPC in combination with ADT and docetaxel in over 85 markets around the world. It's also approved in combination with ADT for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease in more than 85 countries around the world. An approval process in the EU for the treatment of mHSPC in combination with ADT (without docetaxel) is already underway by Bayer. Nubeqa achieved blockbuster status in September 2024, with annual sales reported by Bayer reaching EUR 1.52 billion for the full year of 2024. Darolutamide is developed jointly by Orion and Bayer. About the ARANOTE trial The ARANOTE trial is a randomized, double-blind, placebo-controlled Phase III study designed to assess the efficacy and safety of darolutamide plus ADT in patients with mHSPC. 669 patients were randomized 2:1 to receive 600 mg of darolutamide twice daily or matching placebo in addition to ADT. The primary endpoint of this study is rPFS, measured as time from randomization to date of first documented radiological progressive disease or death due to any cause, whichever occurs first. Secondary endpoints include overall survival (time to death from any cause), time to first castration resistant event, time to initiation of subsequent anti-cancer therapy, time to prostate-specific antigen (PSA) progression, PSA undetectable rates, time to pain progression, and safety assessments. Results from the Phase III ARANOTE trial presented at ESMO 2024 and published in The Journal of Clinical Oncology showed that darolutamide plus ADT significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001), in patients with mHSPC. Consistent benefits in radiological progression-free survival (rPFS) were observed across prespecified subgroups, including patients with high-volume (HR 0.60, 95% CI: 0.44-0.80) and low-volume (HR 0.30, 95% CI: 0.15-0.60) mHSPC. The incidence of adverse events in the treatment group with darolutamide plus ADT in the ARANOTE study was comparable to placebo plus ADT. Darolutamide plus ADT was generally well tolerated and showed lower discontinuation rates due to adverse events compared to placebo plus ADT. About darolutamide Darolutamide is an oral ARi with a unique chemical structure that binds with high affinity to the androgen receptor and exhibits a strong antagonistic effect against the androgen receptor inhibiting the receptor function and the growth of prostate cancer cells. Additionally, preclinical models and neuroimaging data in healthy humans support darolutamide's low potential for blood-brain barrier penetration. Darolutamide (plus ADT or plus ADT and docetaxel) demonstrated a side effect profile in both registrational studies in mHSPC where the incidences of adverse events were roughly similar to the respective comparator arm. Darolutamide is a treatment option for doctors and patients, considering its tolerability and low risk of drug interaction. A robust clinical development program is underway investigating darolutamide across various stages of prostate cancer. The program includes the Phase III ARASTEP trial evaluating darolutamide plus ADT compared to ADT alone in hormone-sensitive high-risk biochemical recurrence (BCR) prostate cancer, who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline. Furthermore, darolutamide is also being investigated by Bayer in the collaborative Phase III DASL-HiCaP (ANZUP1801) trial led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). The study evaluates darolutamide as an adjuvant treatment for localized prostate cancer with very high risk of recurrence. About metastatic hormone-sensitive prostate cancer At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. mHSPC is a stage in the disease where the cancer has spread outside of the prostate to other parts of the body. Up to 10% of men will present with mHSPC when first diagnosed.3,4,5 For patients with mHSPC, ADT is the cornerstone of treatment, in combination with chemotherapy docetaxel and/or an androgen receptor inhibitor (ARi). Despite treatment, most men with mHSPC will eventually progress to castration-resistant prostate cancer (CRPC), a condition with limited survival. Contact person: Tuukka Hirvonen, Investor Relations tel. +358 10 426 2721 References Bray F et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Accessed: September 2024. James ND et al. Lancet 2024; 403: 1683–722. Piombino C et al. Cancers (Basel). 2023 Oct 11;15(20):4945. Helgstrand JT et al. Cancer. 2018;124(14):2931-2938. Buzzoni C et al. Eur. Urol. 2015;68:885–890. Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
